RIGEL PHARMACEUTICALS INC — Director's Dealing 2018

Sep 7, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RIGEL PHARMACEUTICALS INC (RIGL)
CIK: 0001034842
Period of Report: 2018-09-04

Reporting Person: Duliege Anne-Marie (EVP & Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-09-04	Common Stock	M	16500	$2.54	Acquired	16500	Direct
2018-09-04	Common Stock	S	16500	$3.5067	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-09-04	Employe Stock Option (right to buy)	$2.54	M	16500	Disposed	2026-05-05	Common Stock (16500)	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018.

F2: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions ranging from $3.50 to $3.53. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the shares sold at each such separate price.

F3: One fourth (1/4th) of the option vests one (1) year from March 7, 2016 and thereafter the balance of the option vests in equal monthly installments over the next thirty-six (36) months.